Development of Chronic Pancreatitis Biomarkers

慢性胰腺炎生物标志物的开发

• 批准号: 7784156
• 负责人: Teresa A Brentnall
• 金额: $ 77.67万
• 依托单位: UNIVERSITY OF WASHINGTON
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-30 至 2011-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7784156
• 关键词: Admission activity; Algorithms; Arts; Biological Markers; Blood; Blood Tests; Clinical; Data; Development; Diagnosis; Disease; Enzyme-Linked Immunosorbent Assay; Ethnic Origin; Gender; Gold; Health Care Costs; Heterogeneity; Hospitals; Incidence; Measurable; Pancreas; Pancreatic Function Tests; Pancreatitis; Patients; Proteins; Proteome; Proteomics; Recruitment Activity; Societies; Symptoms; Techniques; Technology; Testing; Time; Tissues; Ultrasonography; Work; X-Ray Computed Tomography; base; chronic pancreatitis; cohort; cost; experience; member

DESCRIPTION (provided by applicant): Chronic pancreatitis, a destructive disease of the pancreas, is difficult to diagnosis and can present with a variety of symptoms. The incidence of chronic pancreatitis is not known; hospital admission and discharge summaries suggest at least 60,000 patients in the US per year, however these are under-estimates and it is clear that many patients have occult disease. The financial burden of pancreatitis to society is substantial: with loss of work and health care costs, the burden approaches $2.5 billion annually. There are currently no good bloods tests for the diagnosis of chronic pancreatitis; endoscopic studies and CT scan are the standard approaches for the diagnosis, with endoscopic ultrasound (EUS) combined with pancreatic function tests (PFT) being the most sensitive. We propose a carefully constructed algorithm for the development of biomarkers for chronic pancreatitis. Our technology for candidate biomarkers discovery uses state-of-the- art proteomics. Our group has an excellent experience working together and each member is considered an expert in their applied field. The preliminary data reveals that we can detect the proteins that underlie pancreatitis and we provide proof of principle that the proteins discovered in tissue are measurable in the blood by ELISA. The feasibility of the proposal is further supported by the fact that we have recruited more than one third of the patients required for the study, we demonstrate that the ITRAQ proteomics techniques are robust and accurate, and that there appears to be no problem with heterogeneity in the pancreatitis proteome based on differences in the gender or ethnic origin of the patient. Our preliminary results support our thesis of protein discovery leading to a measurable biomarker for pancreatitis and also demonstrate the ability of the team to work effectively and successfully. The cohort in which the biomarkers will be developed are highly defined and represent the clinical setting in which the biomarker would be used. The initial biomarker studies look promising. An accurate biomarker for chronic pancreatitis would be of enormous clinical benefit and could save time and costs in comparison to the current gold standard of endoscopic testing for the disease.

描述（由申请人提供）：慢性胰腺炎是胰腺的一种破坏性疾病，难以诊断，并可表现出多种症状。慢性胰腺炎的发病率尚不清楚;入院和出院总结表明，美国每年至少有60，000例患者，但这些都被低估了，很明显，许多患者患有隐匿性疾病。胰腺炎给社会带来的经济负担是巨大的：加上失去工作和医疗保健费用，每年的负担接近25亿美元。目前还没有好的血液检查来诊断慢性胰腺炎;内镜检查和CT扫描是标准 内镜超声（EUS）结合胰腺功能检查（PFT）是最敏感的诊断方法。我们提出了一种精心构建的算法来开发慢性胰腺炎的生物标志物。我们的候选生物标志物发现技术使用最先进的蛋白质组学。我们的团队有着良好的合作经验，每个成员都被认为是其应用领域的专家。初步数据表明，我们可以检测胰腺炎的蛋白质，我们提供了原则证明，组织中发现的蛋白质可以通过ELISA在血液中测量。我们招募了超过三分之一的研究所需患者，我们证明ITRAQ蛋白质组学技术是稳健和准确的，并且基于患者性别或种族来源的差异，胰腺炎蛋白质组的异质性似乎没有问题，这进一步支持了该建议的可行性。我们的初步结果支持我们的蛋白质发现论文，导致胰腺炎的可测量生物标志物，也证明了团队有效和成功工作的能力。将开发生物标志物的队列是高度定义的，并代表将使用生物标志物的临床环境。最初的生物标志物研究看起来很有希望。慢性胰腺炎的准确生物标志物将具有巨大的临床益处，与目前内镜检查疾病的金标准相比，可以节省时间和成本。